AbCellera Biologics (ABCL) vs Amylyx Pharmaceuticals (AMLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Amylyx Pharmaceuticals (AMLX) over the past year, gaining 176.1% versus a gain of 77.4%. Amylyx Pharmaceuticals is the larger company by market cap ($3.35 billion vs $3.16 billion), about 1.1 times the size, while AbCellera Biologics is growing revenue faster (+160.6% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | AMLX |
|---|---|---|
| Share price | $9.69 | $26.02 |
| Market cap | $3.16B | $3.35B |
| 1-day change | -7.45% | -0.69% |
| YTD return | +183.33% | +115.40% |
| 1-year return | +176.07% | +77.37% |
| 5-year return | -30.74% | — |
| EPS (TTM) | $-0.48 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $0 |
| Revenue growth (YoY) | +160.56% | -100.00% |
| Net income (latest FY) | $-146.41M | $-144.74M |
| Operating margin | -288.98% | — |
| Net margin | -194.88% | — |
| 52-week high | $15.02 | $41.14 |
| 52-week low | $2.75 | $10.83 |
| Distance from 52-week high | -35.46% | -36.75% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +92.67% | +65.26% |
| Average volume | 4.34M | 1.53M |
| Shares outstanding | 326.62M | 128.56M |
| Employees | 562 | 136 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed AMLX by 98.7 percentage points over the past year.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs -100.00%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
ABCL vs AMLX FAQ
Which is bigger, AbCellera Biologics or Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals (AMLX) is larger, with a market capitalization of $3.35B compared with $3.16B for AbCellera Biologics (ABCL).
Which stock has performed better over the past year, ABCL or AMLX?
ABCL returned +176.07% over the past 12 months, compared with +77.37% for AMLX (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Amylyx Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.